Sidler B, Alpert L, Henderson J E, Deckelbaum R, Amizuka N, Silva J E, Goltzman D, Karaplis A C
Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Canada.
J Clin Endocrinol Metab. 1996 Aug;81(8):2841-7. doi: 10.1210/jcem.81.8.8768840.
PTH-related peptide (PTHrP) is the major factor responsible for humoral hypercalcemia of malignancy. This paraneoplastic syndrome has been described in association with a number of malignancies, but rarely with carcinoma of the colon. Moreover, little is known about the molecular mechanisms that underlie PTHrP overexpression in tumors. Here we report a patient who presented with hypercalcemia 6 months after resection of a neuroendocrine colonic carcinoma (tumor I). At the time of admission, intact PTH was decreased, circulating PTHrP levels were elevated, and there was tumor recurrence (tumor II). Immunohistochemical staining of paraffin-embedded sections from tumor I did not stain for PTHrP, whereas cells from tumor II stained intensely positive. Southern blot analysis and differential PCR of genomic DNAs from tumor specimens and the patient's leukocytes demonstrated amplification of the PTHrP gene in tumor II. Moreover, staining for p53 protein was evident in tumor II, but not in tumor I, consistent with the presence of a mutant form of p53 and associated loss of tumor suppressor function in the recurrent tumor. PTHrP gene amplification was also detected in one of five other tumors associated with humoral hypercalcemia of malignancy. These findings suggest that a potential mechanism contributing to PTHrP overexpression in malignancies is gene amplification, which could arise from increased genomic instability associated with the progressive stages of neoplasia.
甲状旁腺激素相关肽(PTHrP)是导致恶性肿瘤体液性高钙血症的主要因素。这种副肿瘤综合征已被描述与多种恶性肿瘤相关,但很少与结肠癌相关。此外,关于肿瘤中PTHrP过表达的分子机制知之甚少。在此,我们报告一名患者,在切除神经内分泌性结肠癌(肿瘤I)6个月后出现高钙血症。入院时,完整的甲状旁腺激素水平降低,循环中的PTHrP水平升高,且存在肿瘤复发(肿瘤II)。来自肿瘤I的石蜡包埋切片的免疫组织化学染色未显示PTHrP染色,而来自肿瘤II的细胞染色呈强阳性。对肿瘤标本和患者白细胞的基因组DNA进行Southern印迹分析和差异PCR显示,肿瘤II中PTHrP基因发生扩增。此外,肿瘤II中p53蛋白染色明显,但肿瘤I中未染色,这与复发肿瘤中存在p53突变形式及相关肿瘤抑制功能丧失一致。在与恶性肿瘤体液性高钙血症相关的其他五个肿瘤中的一个也检测到PTHrP基因扩增。这些发现表明,导致恶性肿瘤中PTHrP过表达的一个潜在机制是基因扩增,这可能源于与肿瘤进展阶段相关的基因组不稳定性增加。